TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Cambridge Epigenetix Stock

Cambridge Epigenetix Stock

cambridge-epigenetix.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $57.08MM

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.

Buy or sell Cambridge Epigenetix stockLearn more about Cambridge Epigenetix IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Cambridge Epigenetix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Cambridge Epigenetix’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cambridge Epigenetix.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Joanne Mason Ph.D
Vice President, Biomarker Discovery
Vitali Proutski Ph.D
Vice President, Informatics
Bobby Yerramilli-Rao Ph.D
Co-Founder & Chairman
Shankar Balasubramanian
Co-Founder & Chairman of Scientific Advisory Board
Hayden Jeffreys
Chief Operating Officer
Deborah Tonge
Director of Finance
Jason Mellad Ph.D
Chief Executive Officer & Board Member

Board Members

Jason Mellad Ph.D
Shankar Balasubramanian
Tom Hulme
GV
Bobby Yerramilli-Rao Ph.D
Somasundaram Subramaniam
New Science Ventures
Alice Newcombe-Ellis
Ahren Innovation Capital
Martin Murphy Ph.D
Syncona
Roelof Botha
Sequoia Capital
Timothy Rink MD

Frequently Asked Questions About Cambridge Epigenetix’s Stock

plusminus
Can you buy Cambridge Epigenetix’s stock?
Cambridge Epigenetix is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cambridge Epigenetix’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Cambridge Epigenetix’s stock?
Yes, you can sell stock of a private company like Cambridge Epigenetix. Forge can help you sell your Cambridge Epigenetix stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Cambridge Epigenetix’s stock price?
Cambridge Epigenetix is a privately held company and therefore does not have a public stock price. However, you may access Cambridge Epigenetix’s private market stock price with Forge Data.
plusminus
What is Cambridge Epigenetix’s stock ticker symbol?
Cambridge Epigenetix does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Cambridge Epigenetix in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

TechCrunch 03/17/2016
Google’s GV leads $21M Series B in bioscience firm Cambridge Epigenetix – TechCrunch
VC firm GV (née Google Ventures) has made another investment in Europe -- its seventh -- leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix.

Trending Companies

Frequently Asked Questions

Updated on: Apr 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.